Abstract:Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are common and devastating clinical disorders with high mortality and no specific therapy. An excessive inflammatory response results in the progression of ALI/ARDS, and the NLRP3 inflammasome is a key participant in inflammation. Erythropoietin (EPO), which is clinically used for anemia, reportedly exerts pleiotropic effects in ALI. However, whether EPO could protect against lipopolysaccharide (LPS)-induced ALI by regulating the NLRP3 inflammasome and its underlying mechanisms remain poorly elucidated. This study aimed to explore whether the therapeutic effects of EPO rely on the suppression of the NLRP3 inflammasome and the specific mechanisms in an LPS-induced ALI mouse model. ALI was induced in C57BL/6 mice by intraperitoneal (i.p.) injection of LPS (15 mg/kg). EPO was administered intraperitoneally at 5 U/g after LPS challenge. The mice were sacrificed 8 h later. Our findings indicated that application of EPO markedly diminished LPS-induced lung injury by restoring histopathological changes, lessened lung wet/dry (W/D) ratio, protein concentrations in bronchoalveolar lavage fluid (BALF) and myeloperoxidase (MPO) levels. Meanwhile, EPO evidently decreased interleukin-1β (IL-1β) and interleukin-18 (IL-18) secretion, the expression of NLRP3 inflammasome components including pro-IL-1β, NLRP3, and cleaved caspase-1 as well as phosphorylation of nuclear factor-κB (NF-κB) p65, which may be associated with activation of EPO receptor (EPOR), phosphorylation of Janus-tyrosine kinase 2 (JAK2) and signal transducer and activator of transcription 3 (STAT3). However, all the beneficial effects of EPO on ALI and modulation NLRP3 inflammasome were remarkably abrogated by the inhibition of EPOR/JAK2/STAT3 pathway and knockout (KO) of NLRP3 gene. Taken together, this study indicates that EPO can effectively attenuate LPS-induced lung injury in mice by suppressing the NLRP3 inflammasome, which is dependent upon activation of EPOR/JAK2/STAT3 signaling and inhibition of the NF-κB pathway.

Interleukin-18 binding protein attenuates lipopolysaccharide-induced acute lung injury in mice via suppression NF-κB and activation Nrf2 pathway.

The Protective Role of Interleukin-18 Binding Protein in a Murine Model of Cardiac Ischemia/reperfusion Injury.

Effects of Zinc Finger Protein A20 on Lipopolysaccharide (Lps)-Induced Pulmonary Inflammation/Anti-Inflammatory Mediators in an Acute Lung Injury/Acute Respiratory Distress Syndrome Rat Model.

Neutralization of IL-18 by IL-18 binding protein ameliorates bleomycin-induced pulmonary fibrosis via inhibition of epithelial-mesenchymal transition.

USP18 mitigates lipopolysaccharide-induced oxidative stress and inflammation in human pulmonary microvascular endothelial cells through the TLR4/NF-κB/ROS signaling

Suppressed nuclear factor-kappa B alleviates lipopolysaccharide-induced acute lung injury through downregulation of CXCR4 mediated by microRNA-194.

Inhibition of Cathepsin L Ameliorates Inflammation Through the A20/NF-κB Pathway in Endotoxin-Induced Acute Lung Injury

Inhibition of PKR Ameliorates Lipopolysaccharide-Induced Acute Lung Injury by Suppressing NF-κB Pathway in Mice.

Metrnl/IL-41 Alleviates Lipopolysaccharide-Induced Acute Lung Injury by Suppressing Inflammatory Responses Through the AMPK/SIRT1 Signaling Pathway

SB203580 Protects Against Inflammatory Response and Lung Injury in a Mouse Model of Lipopolysaccharide‑induced Acute Lung Injury.

Examination of the Protective Effect of 6-Shogaol Against LPS-induced Acute Lung Injury in Mice Via NF-kB Attenuation

Protective Effects of Polydatin on Lipopolysaccharide-Induced Acute Lung Injury Through TLR4-MyD88-NF-κB Pathway

Protective Role of TNFR-Fc in Mouse Acute Lung Injury Induced by Lipopolysaccharide

The suppression of nuclear factor kappa B/microRNA 222 axis alleviates lipopolysaccharide-induced acute lung injury through increasing the alkylglyceronephosphate synthase expression

Inhibition of protein kinase C alpha attenuates lipopolysaccharide-triggered acute lung injury by alleviating the hyperinflammatory response and oxidative stress

Protective Effect of Piceatannol Against Acute Lung Injury Through Protecting the Integrity of Air-Blood Barrier and Modulating the TLR4/NF-κB Signaling Pathway Activation.

Interleukin-18 and IL-18 Binding Protein

JNK‑IN‑8 Treatment Alleviates Lipopolysaccharide‑induced Acute Lung Injury Via Suppression of Inflammation and Oxidative Stress Regulated by JNK/NF‑κB Signaling.

Suppression of NLRP3 Inflammasome by Erythropoietin via the EPOR/JAK2/STAT3 Pathway Contributes to Attenuation of Acute Lung Injury in Mice

Aspirin-triggered Lipoxin A4 Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Inhibiting Activation of Mitogen-Activated Protein Kinases and NF-κB in Mice.

An antibody to IL-1 receptor 7 protects mice from LPS-induced tissue and systemic inflammation